Polyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery Platform
Event summary
- Polyrizon submitted amended claims to its U.S. patent application on May 4, 2026, expanding protection to include drug delivery systems and methods of use.
- The expanded claims cover compositions with sulfated polysaccharide polymers and additional polymeric components for improved API delivery.
- The platform aims to enhance drug residence time, bioavailability, and controlled film formation on mucosal surfaces.
- Polyrizon's technology is designed for both local and systemic drug administration via intranasal delivery.
The big picture
Polyrizon's patent expansion aligns with its strategy to fortify its global IP portfolio, a critical move in the competitive biotech landscape where intellectual property often dictates market access and licensing opportunities. The broader trend of enhancing drug delivery systems through mucoadhesive technologies highlights the industry's shift toward improving bioavailability and patient compliance. Polyrizon's focus on intranasal hydrogels positions it within the growing niche of non-invasive, targeted therapies.
What we're watching
- Patent Approval
- Whether the amended claims will be approved and in a form advantageous to Polyrizon.
- Market Applicability
- The pace at which Polyrizon can leverage the expanded IP to enter new therapeutic areas.
- Competitive Positioning
- How the strengthened IP portfolio will affect Polyrizon's standing against competitors in intranasal drug delivery.
Related topics